BTAI
NASDAQBioXcel Therapeutics Inc.
Price$1.11-0.01 (-0.89%)
01:30 PM07:45 PM
News · 26 weeks60-25%
2025-12-142026-06-07
Mix3290d
- Insider12(38%)
- SEC Filings10(31%)
- Other8(25%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- PRBioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual MeetingNEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL. Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safe
- INSIDERChief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDEROfficer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERCEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SECSEC Form 144 filed by BioXcel Therapeutics Inc.144 - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECSEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.SCHEDULE 13G - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECSEC Form 10-Q filed by BioXcel Therapeutics Inc.10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsFDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026. In the quarter ended on March 31, the
- INSIDERCEO and President Mehta Vimal converted options into 18,000 shares, increasing direct ownership by 85% to 39,259 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 9,000 shares, increasing direct ownership by 135% to 15,645 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Scientific Officer Yocca Frank converted options into 9,000 shares, increasing direct ownership by 138% to 15,520 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDEROfficer Rodriguez Javier converted options into 9,000 shares, increasing direct ownership by 131% to 15,863 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingLive event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. The event will center on the Company's ongoing launch strategy initiatives ahead of the November 14 PDUFA target action date of IGALMI® for the treatment of acute agitation associated with bipolar disorders and schizophrenia in th
- PRBioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsDoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for management of acute stress reactions (ASR) NEW HAVEN, Conn., April 08, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the enrollment of the first patients in a U.S. Department of War (DoW)-funded Phase 2a clinical trial evaluating BXCL501 (sublingual dexmedetomidine) for the treatment of acute stress rea
- PRBioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingPDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has a
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECSEC Form S-8 filed by BioXcel Therapeutics Inc.S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECSEC Form 10-K filed by BioXcel Therapeutics Inc.10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingsNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readines
- ANALYSTRodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price targetRodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00
BTAI FAQ
7 questionsWhat does BioXcel Therapeutics Inc. do?
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA...Where does BTAI stock trade?
BioXcel Therapeutics Inc. (BTAI) is listed on NASDAQ.What sector and industry is BTAI in?
BioXcel Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BioXcel Therapeutics Inc. go public?
BioXcel Therapeutics Inc. (BTAI) completed its IPO in 2018.What are analysts saying about BTAI?
BioXcel Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $1700.00 price target on 2026-03-17.What companies are similar to BTAI?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), TNYA (Tenaya Therapeutics Inc.), APLT (Applied Therapeutics Inc.), NBSE (NeuBase Therapeutics Inc.). Compare BTAI side-by-side with any of them on Quantisnow.How can I track BTAI on Quantisnow?
Quantisnow aggregates BioXcel Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BTAI to receive live email and push alerts on every new disclosure.